Comparative outcomes of ipilimumab & nivolumab dosing in melanoma скачать в хорошем качестве

Comparative outcomes of ipilimumab & nivolumab dosing in melanoma

Hildur Helgadottir, MD, Karolinska University Hospital, Stockholm, Sweden, discusses real-world outcomes of two nivolumab plus ipilimumab dosing regimens in advanced melanoma: ipilimumab 1 mg/kg with nivolumab 3 mg/kg (NIVO3+IPI1) versus ipilimumab 3 mg/kg with nivolumab 1 mg/kg (NIVO1+IPI3). Higher response rates, longer progression-free and overall survival, and lower grade 3–5 adverse events with NIVO3+IPI1 were reported, likely due to improved tolerability and treatment completion. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.